Plecanatide Benefits: Evidence, Verdict, and Limits
Plecanatide has its strongest evidence for Chronic Idiopathic Constipation Relief, Diarrhea (Adverse), and IBS-C Symptom Improvement. ExaminePeptides rates the overall file Level A and classifies the current research status as FDA Approved. Plecanatide (Trulance) is FDA-approved for chronic idiopathic constipation and IBS with constipation, with Phase 3 RCTs demonstrating consistent efficacy on validated endpoints. As a uroguanylin analog that works locally in the GI tract with minimal systemic absorption, it has an excellent safety profile. For guanylate cyclase-C agonist research and IBS-C/CIC treatment, it is a validated option alongside linaclotide.
Direct Answer
Plecanatide (Trulance) is FDA-approved for chronic idiopathic constipation and IBS with constipation, with Phase 3 RCTs demonstrating consistent efficacy on validated endpoints. As a uroguanylin analog that works locally in the GI tract with minimal systemic absorption, it has an excellent safety profile. For guanylate cyclase-C agonist research and IBS-C/CIC treatment, it is a validated option alongside linaclotide.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- IBS-C, chronic idiopathic constipation, guanylate cyclase-C agonism research
Best-Supported Benefits
- Chronic Idiopathic Constipation Relief: Level A, includes human evidence - Phase 3 trials demonstrate significant improvement in complete spontaneous bowel movements (CSBMs) compared to placebo. Approximately 21% of patients achieved primary endpoint vs. 10% placebo.
- IBS-C Symptom Improvement: Level A, includes human evidence - Significant improvement in both abdominal pain and bowel movement frequency in IBS-C patients. FDA-approved for this indication based on rigorous Phase 3 data.
- Diarrhea (Adverse): Level A, includes human evidence - Diarrhea is the most common adverse effect, occurring in approximately 2-5% of patients. Usually mild and self-limiting but may lead to discontinuation.
Evidence Quality
Plecanatide is rated Level A. The current research status is FDA Approved. Stronger human evidence is separated from animal, cell, or early-stage findings.
Safety Context
- Contraindicated in patients under 6 years of age (risk of serious dehydration)
- Avoid use in patients 6 to less than 18 years of age
- Discontinue if severe diarrhea occurs
- Minimal systemic absorption limits drug interactions but does not eliminate them
- Monitor for dehydration in elderly patients
Primary Sources
- Efficacy and safety of plecanatide in patients with chronic idiopathic constipation. Am J Gastroenterol, 2017.
- Plecanatide for irritable bowel syndrome with constipation: Phase 3 trial results. Am J Gastroenterol, 2018.
- Uroguanylin and guanylin peptide analogs as regulators of intestinal function. World J Gastroenterol, 2015.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Chronic Idiopathic Constipation Relief (Level A), IBS-C Symptom Improvement (Level A), and Diarrhea (Adverse) (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Plecanatide Benefits: Evidence, Verdict, and Limits." Last reviewed 2026-04-04. https://examinepeptides.com/answers/plecanatide-benefits-evidence/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.